Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges
- 1 August 2011
- journal article
- review article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of neurosurgery. Pediatrics
- Vol. 8 (2) , 135-148
Abstract
Object: Brain tumors are the most common category of childhood solid tumors. In the 1970s and 1980s, treatment protocols for benign tumors focused almost exclusively on surgery, with radiation treatment as a salvage modality, whereas the management of malignant tumors employed a combination of surgery, radiation therapy, and chemotherapy, with therapeutic approaches such as “8-in-1” chemotherapy often applied across histological tumor subsets that are now recognized to be prognostically distinct. During the ensuing years, treatment has become increasingly refined, based on clinical and, more recently, molecular factors, which have supported risk-adapted treatment stratification. The goal of this report is to provide an overview of recent progress in the field. Methods: A review of the literature was undertaken to examine recent advances in the management of the most common childhood brain tumor subsets, and in particular to identify instances in which molecular categorization and treatment stratification offer evidence or promise for improving outcome. Results: For both medulloblastomas and infant tumors, refinements in clinical and molecular stratification have already facilitated efforts to achieve risk-adapted treatment planning. Current treatment strategies for children with these tumors focus on improving outcome for tumor subsets that have historically been relatively resistant to therapy and reducing treatment-related sequelae for children with therapy-responsive tumors. Recent advances in molecular categorization offer the promise of further refinements in future studies. For children with ependymomas and low-grade gliomas, clinical risk stratification has facilitated tailored approaches to therapy, with improvement of disease control and concomitant reduction in treatment sequelae, and recent discoveries have identified promising therapeutic targets for molecularly based therapy. In contrast, the prognosis remains poor for children with diffuse intrinsic pontine gliomas and other high-grade gliomas, despite recent identification of biological correlates of tumor prognosis and elucidation of molecular substrates of tumor development. Conclusions: Advances in the clinical and molecular stratification for many types of childhood brain tumors have provided a foundation for risk-adapted treatment planning and improvements in outcome. In some instances, molecular characterization approaches have also yielded insights into new therapeutic targets. For other tumor types, outcome remains discouraging, although new information regarding the biological features critical to tumorigenesis are being translated into novel therapeutic approaches that hold promise for future improvements.Keywords
This publication has 116 references indexed in Scilit:
- A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomasEuropean Journal of Cancer, 2010
- Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumorsPediatric Blood & Cancer, 2010
- Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing programPediatric Blood & Cancer, 2010
- Cross-species genomics matches driver mutations and cell compartments to model ependymomaNature, 2010
- Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year updateJournal of Neuro-Oncology, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Frequent Amplification of a chr19q13.41 MicroRNA Polycistron in Aggressive Primitive Neuroectodermal Brain TumorsCancer Cell, 2009
- Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449New England Journal of Medicine, 2009
- Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumorsPediatric Blood & Cancer, 2008
- Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomasJournal of Neuro-Oncology, 2008